BioWorld

Oct. 27, 2010

Bullseye: MacroGenics Back on Target with Double DART Deals

After learning late last week that lead program teplizumab failed to meet its primary endpoint in a Phase III trial for Type 1 diabetes, MacroGenics Inc. President and CEO Scott Koenig was disappointed, but philosophical. (BioWorld Today) Read More

IDC Signs MedImmune to First Vaccine Adjuvant Partnership

Ariad Topples 9.5% on Stock Offering to Fund Cancer Drug

Karo Bio Rakes in $80M for Eprotirome Development

Amgen Treading Water Ahead of Anticipated Dmab SRE Nod

Savient Moves on with Gout Drug Launch Despite No Buyer

Clinic Roundup

Other News To Note

Stock Movers

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...